Recruiting
Phase 1
Phase 2

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Sponsor:

Qurient Co., Ltd.

Code:

NCT05438420

Conditions

Esophageal Cancer

Gastric Cancer

Hepatocellular Cancer

Cervical Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Q702

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information